Answer: C. Ra-223 is currently approved for treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. It is not approved for patients with visceral metastases or those without bone metastases. Lutetium-177–labeled PSMA-617 (LuPSMA), not Ra-223, is approved for treatment of PSMA-positive mCRPC.
